CYT, IMO, could be a good biotech shares to buy. However, IMO, it has two weakness:
(1) CEO, Andrew, knows finance more than science, and may not be able to guide the company into a better shape it could be;
(2) Cash position is low and this is the reason why they try to get the cash box like Progen.
However, CYT does have a good point which its Chairman is quite rich to support this company.
bought at 58, page-139
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
